Immunotherapy with the storage mite lepidoglyphus destructor.
We carried out a double-blind clinical trial of immunotherapy on 35 patients sensitized to the storage mite Lepidoglyphus destructor (Ld). Before and after 12 months of specific hyposensitization (Abelló Lab., Spain) we performed in vivo (skin tests with Ld, methacholine and challenge tests), and in vitro tests (specific IgE, IgG, IgG1 and IgG4 to Ld and specific IgE, IgG, IgG1 and IgG4 to their major allergen Lep dI). We also monitored the efficacy and safety of the immunotherapy with clinical and analytical controls (symptoms and medication score, detection of immune complexes). After therapy we found a significant decrease in specific skin reactivity, dose of positive challenge tests, and hyperresponsiveness to methacholine. Sputum eosinophilia decreased. Specific IgE to Ld was increased and we also observed an increase in specific IgG1 and IgG4 to Ld and Lep DI. The placebo group showed no changes in these variables. There were no severe secondary reactions after treatment with the extract. Patients-self-evaluation was favourable and their labour absence decreased. No development of circulating immune complexes was associated with this immunotherapy.
Armentia-Medina
A
A
Division of Allergy and Pneumology, Rio Hortega Hospital, University of Valladolid, Spain.
Tapias
J A
JA
Martín
J F
JF
Ventas
P
P
Fernández
A
A
D000293:Adolescent; D000328:Adult; D000485:Allergens; D000818:Animals; D002648:Child; D003233:Conjunctivitis, Allergic / Q000276:immunology / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D008925:Mites; D012221:Rhinitis, Allergic, Perennial / Q000276:immunology / Q000628:therapy*
D000485:Allergens